The Prognostic and Immune Significance of CILP2 in Pan-Cancer and Its Relationship with the Progression of Pancreatic Cancer
Cartilage intermediate layer protein 2 ( ) facilitates interactions between matrix components in cartilage and has emerged as a potential prognostic biomarker for cancer. This study aimed to investigate the function and mechanisms of in pan-cancer. We evaluated the pan-cancer expression, methylation...
Saved in:
Published in | Cancers Vol. 15; no. 24; p. 5842 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
14.12.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Cartilage intermediate layer protein 2 (
) facilitates interactions between matrix components in cartilage and has emerged as a potential prognostic biomarker for cancer. This study aimed to investigate the function and mechanisms of
in pan-cancer. We evaluated the pan-cancer expression, methylation, and mutation data of
for its clinical prognostic value. Additionally, we explored the immunological characteristics of
in pan-cancer and then focused specifically on pancreatic ductal adenocarcinoma (PAAD). The subtype analysis of PAAD identified subtype-specific expression and immunological characteristics. Finally, in vitro and in vivo experiments assessed the impact of
on pancreatic cancer progression.
exhibited high expression in most malignancies, with significant heterogeneity in epigenetic modifications across multiple cancer types. The abnormal methylation and copy number variations in
were correlated with poor prognoses. Upregulated
was associated with
/
and more malignant subtypes.
exhibited a negative correlation with immune checkpoints in PAAD, suggesting potential for immunotherapy.
activated the AKT pathway, and it increased proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) in pancreatic cancer. We demonstrated that
significantly contributes to pancreatic cancer progression. It serves as a prognostic biomarker and a potential target for immunotherapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2072-6694 2072-6694 |
DOI: | 10.3390/cancers15245842 |